nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

2021161 citationsJournal Articlebronze Open Access

Authors

Andrew J. Wagner · Roche (Switzerland)

Vinod Ravi · Roche (Switzerland)

Richard F. Riedel · Roche (Switzerland)

Kristen N. Ganjoo · Roche (Switzerland)

Brian A. Van Tine · Roche (Switzerland)

Rashmi Chugh · Roche (Switzerland)

Lee D. Cranmer ·

Abstract

nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.

Topics & Keywords

Tuberous Sclerosis Complex Research Vascular Tumors and Angiosarcomas Neurofibromatosis and Schwannoma Cases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 33, pp. 3660-3670

DOI: 10.1200/jco.21.01728

Field-Weighted Citation Impact: 12.85

Command Palette

<i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Authors

Abstract

Topics & Keywords

UN Sustainable Development Goals

Publication Details